Annals of Oncology Hematology

Eight-year outcomes of testosterone suppression plus enzalutamide or a nonsteroidal antiandrogen for metastatic hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304)

Elsevier ·

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →